Truist lowered the price target for the Adverum Biotechnologies Inc. (NASDAQ:ADVM) stock from “a Buy” to “a Hold”. The rating was released on April 29, 2021. The research report from Chardan Capital Markets has downgraded the stock from Buy to Neutral, with a price target set at $5. The stock was initiated by UBS, who disclosed in a research note on December 16, 2020, to Neutral and set the price objective to $13.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.39 during the last quarter as opposed to a consensus estimate of -$0.32, which indicates the company missed its estimate by -$0.07, which implies that the company surprised the market by -21.90%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is -$0.38. This is an average of 8 analysts’ earnings, where the high earnings per share estimate is -$0.33 and the low earnings per share estimate is -$0.41.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Adverum Biotechnologies Inc. (NASDAQ:ADVM) dipped -62.30% to close Thursday’s market session at $3.83, lower as compared to yesterday’s close. The stock price fluctuated between $3.78 and $4.46 throughout the trading session with the volume trading being 38874877 shares, which represented a significant variation when compared to the three months average volume of 806.18K shares. The firm’s stock price fluctuated -59.94% within the last five trades and -59.47% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -68.56% in the last 6 months and -68.79% was subtracted to its value over the previous 3 months. ADVM stock is trading at a margin of -59.78%, -63.84% and -69.35% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ADVM deals in the Healthcare domain. The stock is trading -85.80 percent below its 52-week high and -55.36 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -54.75. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Adverum Biotechnologies Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $377.45 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 0.86, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.30 percent of Adverum Biotechnologies Inc. shares are owned by insiders, and 98.80 percent are held by financial institutions. Fischer Laurent, the CEO and Director at Adverum Biotechnologies Inc. (ADVM) has bought 10,000 shares of firm on Mar 24 at a price of $9.88 against the total amount of $98780.0. In another inside trade, Machado Patrick, Director of Adverum Biotechnologies Inc. (NASDAQ:ADVM) bought 10,000 shares of the firm on Mar 24 for a total worth of $99196.0 at a price of $9.92. An inside trade which took place on Feb 09, President and CFO of Adverum Biotechnologies Inc. PATTERSON LEONE D sold 12,533 shares of firm against total price of $0.18 million at the cost of $14.10 per share.